|Altimmune Inc., of Gaithersburg, Md.||Nasoshield||Intranasal anthrax vaccine||Anthrax prophylaxis||Completed enrollment of 42 healthy subjects; immunogenicity data expected in the fourth quarter of 2020|
|Everest Medicines Ltd., of Shanghai||FGF-401||ATP-competitive, reversible-covalent inhibitor of FGFR4||Advanced solid tumors||First of up to 70 patients treated in the phase Ib/II study testing FGF-401 plus Keytruda (pembrolizumab, Merck & Co. Inc.)|
|Oncopeptides AB, of Stockholm||Melflufen||Peptide-drug conjugate targeting aminopeptidases||Immunoglobulin light chain amyloidosis||First patient enrolled in phase I/II study testing melflufen plus dexamethasone after at least 1 prior line of therapy|
|Oncolys Biopharma Inc., of Tokyo||Telomelysin (OBP-301)||Telomerase modulator||Recurrent, inoperable head and neck cancer||Investigator-initiated study planned to evaluate telomelysin plus Keytruda (pembrolizumab, Merck & Co. Inc.) and stereotactic radiation|
|Ligand Pharmaceuticals Inc., of San Diego, and Cstone Pharmaceuticals Co. Ltd., of Suzhou, China||CS-1001||Monoclonal antibody targeting PD-L1||First-line treatment of stage IV squamous and non-squamous non-small-cell lung cancer||CS-1001 plus chemotherapy produced a progression-free survival of 7.8 months compared to 4.9 months for chemotherapy alone (p<0.0001)|
|Roche Holding AG, of Basel, Switzerland||Tecentriq (atezolizumab)||Monoclonal antibody targeting PD-L1||First-line, PD-L1-positive, metastatic triple-negative breast cancer||The Impassion131 study testing Tecentriq plus paclitaxel didn't meet the primary endpoint of progression-free survival; overall survival showed a negative trend|
|Satsuma Pharmaceuticals Inc., of South San Francisco||STS-101||Intranasal dry powder formulation of dihydroergotamine mesylate||Migraine||Started enrollment in the 300-patient Ascend study to test the long-term safety of STS-101 as an as-needed acute treatment; secondary endpoints include efficacy evaluations|
For more information about individual companies and/or products, see Cortellis.